ESR2 and central nervous system cancer: Using the novel highly selective ERβ agonist liquiritigenin and TMZ-resistant U138 glioma cells, Liu et al. [27] suggested that liquiritigenin treatment could enhance glioma cell susceptibility to TMZ through inhibiting the PI3K/AKT/mTOR pathway.